Study of HB0025 plus nab-paclitaxel for first-line TNBC
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug (HB0025) combined with chemotherapy (nab-paclitaxel) as the first treatment for people with triple-negative breast cancer that has spread or cannot be removed by surgery. It aims to see if this combination works better than standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have triple-negative breast cancer (meaning tests show no HER2, estrogen, or progesterone receptors) that has spread or is locally advanced and cannot be removed by surgery.
- You have not had any previous chemotherapy or other cancer treatment for advanced or metastatic triple-negative breast cancer.
- You are in good enough health to be up and doing light activity (ECOG 0 or 1).
- You have at least one tumor that can be measured on scans.
- You have no history of severe allergic reactions to drugs, especially antibodies or similar treatments.
- You have not had prior treatment with drugs that target PD-1/PD-L1 or VEGF proteins.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different drug combinations given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see which combination works better and has fewer side effects.
This trial tests a new immunotherapy drug called AK112 combined with chemotherapy (nab-paclitaxel) for people with advanced triple-negative breast cancer who haven't had treatment yet. The goal is to see if AK112 works better than a placebo at shrinking tumors and helping people live longer.
This trial tests a new drug called BL-B01D1 combined with an immunotherapy (PD-1 antibody) against a standard chemo/immu-notherapy combination. It is for people with previously untreated, advanced triple-negative breast cancer whose tumors have a protein called PD-L1.
This trial tests a combination of four drugs—two immunotherapies (QL1706), an anti-angiogenic agent (anlotinib), and chemotherapy (nab-paclitaxel)—as a first-line treatment for advanced triple-negative breast cancer. The goal is to see if this combination slows or stops cancer growth better than standard treatment alone.
This trial tests whether adding an experimental immunotherapy drug (QL1706) with or without bevacizumab to standard chemotherapy can help people with advanced triple-negative breast cancer that hasn't been treated yet. It aims to improve outcomes for patients who have already had earlier treatment but whose cancer has come back or spread.
This trial tests a new drug called HB0025 combined with chemotherapy for people with advanced non-squamous non-small cell lung cancer who haven't had treatment before. It compares this combination to the current standard treatment (tislelizumab plus chemo) to see which works better.
Hear when a new TNBC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.